# Title

 Food and Drugs. PART 211â€”CURRENT GOOD MANUFACTURING PRACTICE FOR FINISHED PHARMACEUTICALS


# ID

 CFR-2018-title21-vol4.Pt. 211


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['maximum', 'more than', 'before', 'after', 'prior to', 'minimum', 'less than', 'at least', 'within']                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Duration    | ['3.0 year', '3 month', '30.0 day', '1.0 year', '6 month']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Condition   | ['subject to', 'until', 'as soon as', 'where', 'provided that', 'when', 'unless', 'if']                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Entities    | ['Distribution', 'Scope', 'Such', 'Master', 'Food', 'Receipt', 'Portable', 'Calculation', 'Input', 'Prior', 'Equipment', 'Ventilation', 'Organoleptic', 'Batch', 'Dates', 'Laboratory', 'Penicillin', 'Packaging', 'Research', 'Adequate', 'Sewage', 'Trash', 'Drugs', 'Access', 'United States Pharmacopeia', 'Design', 'Sanitation', 'Expiration', 'Written', 'Fungicide', 'Reserve', 'Plumbing', 'Research and Testing', 'Automatic', 'Specific', 'Actual', 'Request', 'New', 'Accelerated', 'Personnel', 'Examination', 'Potable', 'Drug', 'Maintenance'] |
| Date        | ['2018-03-01', '1978-09-29']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                                    |
|:--------------|:-------------------------------------------------------------------------------------------------------------------------------------------|
| minimum       | (a) The regulations in this part contain the  minimum current good manufacturing practice for preparation of drug                          |
| within        | human foods, and which products may also fall within the legal definition of drugs by virtue of                                            |
| within        | (c) Operations shall be performed  within  specifically defined areas of adequate size.                                                    |
| before        | testing, or examination by the quality control unit before release for manufacturing or packaging; (2) Holding rejected                    |
| before        | testing, or examination by the quality control unit before release for manufacturing or packaging; (2) Holding rejected                    |
| before        | (6) Packaging and labeling operations;                                                                                                     |
|               |                       (7) Quarantine storage  before release of drug products; (8) Storage of drug                                         |
| after         | of drug products; (8) Storage of drug products after release; (9) Control and laboratory operations; (10) Aseptic                          |
| prior to      | identification; (5) Protection of clean equipment from contamination prior to use; (6) Inspection of equipment for cleanliness immediately |
| before        | use; (6) Inspection of equipment for cleanliness immediately before  use.                                                                  |
| maximum       | is necessary, an additional nonfiber-releasing filter having a maximum nominal pore size rating of 0.2 micron (0.45                        |
| before        | (a) Upon receipt and  before acceptance, each container or grouping of containers of                                                       |
| within        | Storage  within the area shall conform to the requirements of                                                                              |
| at least      | identity of each component of a drug product. at least                                                                                     |
| at least      | from the supplier of a component, provided that at least one specific identity test is conducted on such                                   |
| at least      | may be accepted from the supplier, provided that at least a visual identification is conducted on such containers/closures                 |
| before        | intended use shall be subjected to microbiological tests before  use.                                                                      |
| after         | unit in accordance with &#167;&#8201;211.84 as necessary, e.g., after  storage for long periods or                                         |
| after         | unit in accordance with &#167;&#8201;211.84 as necessary, e.g., after  storage for long periods or                                         |
| within        | be attached to a medical gas supply system within a hospital, health care entity, nursing home, other                                      |
| less than     | be formulated with the intent to provide not less than 100 percent of the labeled or established amount                                    |
| after         | at commencement or completion of significant phases or after  storage for long periods.                                                    |
| before        | sampled, and examined or tested upon receipt and before use in packaging or labeling of a drug                                             |
| after         | a 100-percent examination for correct labeling during or after completion of finishing operations; or (3) Use of                           |
| after         | a 100-percent examination for correct labeling during or after completion of finishing operations; or (3) Use of                           |
| before        | packaging and labeling materials for suitability and correctness before packaging operations, and documentation of such examination in     |
| before        | Inspection of the packaging and labeling facilities immediately before use to assure that all drug products have                           |
| within        | the drug class, and a list of products within  that class.                                                                                 |
| before        | labeling required by this regulation may be made before FDA approval, as provided under &#167;&#8201;314.70(c) of this                     |
| at least      | bear dosage limitations and they are stable for at least  3 years as supported by appropriate stability data.                              |
| before        | They shall include:                                                                                                                        |
|               |                       (a) Quarantine of drug products  before  release by the quality control unit.                                        |
| within        | written specifications for the acceptance of each lot within each shipment of components, drug product containers, closures,               |
| prior to      | the identity and strength of each active ingredient, prior to  release.                                                                    |
| prior to      | of shortlived radiopharmaceuticals, such batches may be released prior to completion of sterility and/or pyrogen testing, provided such    |
| prior to      | appropriate standards, specifications, and any other relevant criteria. prior to                                                           |
| after         | (as directed in the labeling) as well as after  they are reconstituted.                                                                    |
| at least      | shall be a written assessment of stability based at least on testing or examination of the drug product                                    |
| at least      | The reserve sample consists of  at least twice the quantity necessary for all tests required                                               |
| after         | reserve sample shall be retained for 1 year after the expiration date of the last lot of                                                   |
| after         | sample shall be retained for: (i) Three months after the expiration date of the last lot of                                                |
| after         | sample shall be retained for: (i) Three months after the expiration date of the last lot of                                                |
| more than     | expiration dating period of the drug product is more than  30 days.                                                                        |
| after         | reserve sample shall be retained for 3 years after distribution of the last lot of the drug                                                |
| at least      | The reserve sample consists of  at least twice the quantity necessary to perform all the                                                   |
| at least      | by acceptable statistical procedures shall be examined visually at least once a year for evidence of deterioration unless                  |
| after         | reserve sample shall be retained for 1 year after  the expiration date of the drug product.                                                |
| after         | sample shall be retained for: (i) Three months after the expiration date of the drug product if                                            |
| after         | sample shall be retained for: (i) Three months after the expiration date of the drug product if                                            |
| more than     | expiration dating period of the drug product is more than  30 days.                                                                        |
| after         | reserve sample must be retained for 3 years after the lot or batch of drug product is                                                      |
| at least      | of a drug product shall be retained for at least 1 year after the expiration date of the                                                   |
| after         | shall be retained for at least 1 year after the expiration date of the batch or, in                                                        |
| after         | shall be retained for at least 1 year after the expiration date of the batch or, in                                                        |
| at least      | components, drug product containers, closures, and labeling for at least 1 year after the expiration date or, in                           |
| after         | closures, and labeling for at least 1 year after the expiration date or, in the case of                                                    |
| after         | closures, and labeling for at least 1 year after the expiration date or, in the case of                                                    |
| at least      | that data therein can be used for evaluating, at least annually, the quality standards of each drug product                                |
| maximum       | (7) A statement of theoretical yield, including the maximum and minimum percentages of theoretical yield beyond which                      |
| minimum       | statement of theoretical yield, including the maximum and minimum percentages of theoretical yield beyond which investigation according    |
| before        | (6) Inspection of the packaging and labeling area before and after use; (7) A statement of the                                             |
| after         | of the packaging and labeling area before and after use; (7) A statement of the actual yield                                               |
| before        | determine compliance with all established, approved written procedures before  a batch is released or distributed.                         |
| maximum       | (including a percentage of theoretical yield exceeding the maximum or minimum percentages established in master production and             |
| minimum       | percentage of theoretical yield exceeding the maximum or minimum percentages established in master production and control records)         |
| at least      | verify that the modification produced results that are at least as accurate and reliable for the material being                            |
| at least      | involving a drug product shall be maintained until at least 1 year after the expiration date of the                                        |
| after         | shall be maintained until at least 1 year after the expiration date of the drug product, or                                                |
| after         | shall be maintained until at least 1 year after the expiration date of the drug product, or                                                |
| after         | written records shall be maintained for 3 years after  distribution of the drug product.                                                   |
| before        | drug products have been held, stored, or shipped before or during their return, or if the condition                                        |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.0 year   | (h) Pending consideration of a proposed exemption, published in the Federal Register of September 29, 1978, the requirements in this section shall not be enforced for human OTC drug products if their labeling does not bear dosage limitations and they are stable for at least 3 years as supported by appropriate stability data.                                                                                                                 |
| 1.0 year   | The retention time is as follows:                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |                       (1) For an active ingredient in a drug product other than those described in paragraphs (a) (2) and (3) of this section, the reserve sample shall be retained for 1 year after the expiration date of the last lot of the drug product containing the active ingredient.                                                                                                                                                         |
| 3 month    | (2) For an active ingredient in a radioactive drug product, except for nonradioactive reagent kits, the reserve sample shall be retained for:                                                                                                                                                                                                                                                                                                          |
|            |                       (i) Three months after the expiration date of the last lot of the drug product containing the active ingredient if the expiration dating period of the drug product is 30 days or less; or                                                                                                                                                                                                                                       |
|            |                       (ii) Six months after the expiration date of the last lot of the drug product containing the active ingredient if the expiration dating period of the drug product is more than 30 days.                                                                                                                                                                                                                                         |
| 30.0 day   | (2) For an active ingredient in a radioactive drug product, except for nonradioactive reagent kits, the reserve sample shall be retained for:                                                                                                                                                                                                                                                                                                          |
|            |                       (i) Three months after the expiration date of the last lot of the drug product containing the active ingredient if the expiration dating period of the drug product is 30 days or less; or                                                                                                                                                                                                                                       |
|            |                       (ii) Six months after the expiration date of the last lot of the drug product containing the active ingredient if the expiration dating period of the drug product is more than 30 days.                                                                                                                                                                                                                                         |
| 6 month    | (2) For an active ingredient in a radioactive drug product, except for nonradioactive reagent kits, the reserve sample shall be retained for:                                                                                                                                                                                                                                                                                                          |
|            |                       (i) Three months after the expiration date of the last lot of the drug product containing the active ingredient if the expiration dating period of the drug product is 30 days or less; or                                                                                                                                                                                                                                       |
|            |                       (ii) Six months after the expiration date of the last lot of the drug product containing the active ingredient if the expiration dating period of the drug product is more than 30 days.                                                                                                                                                                                                                                         |
| 30.0 day   | (2) For an active ingredient in a radioactive drug product, except for nonradioactive reagent kits, the reserve sample shall be retained for:                                                                                                                                                                                                                                                                                                          |
|            |                       (i) Three months after the expiration date of the last lot of the drug product containing the active ingredient if the expiration dating period of the drug product is 30 days or less; or                                                                                                                                                                                                                                       |
|            |                       (ii) Six months after the expiration date of the last lot of the drug product containing the active ingredient if the expiration dating period of the drug product is more than 30 days.                                                                                                                                                                                                                                         |
| 3.0 year   | (3) For an active ingredient in an OTC drug product that is exempt from bearing an expiration date under &#167;&#8201;211.137, the reserve sample shall be retained for 3 years after distribution of the last lot of the drug product containing the active ingredient.                                                                                                                                                                               |
| 1.0 year   | The retention time is as follows:                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |                       (1) For a drug product other than those described in paragraphs (b) (2) and (3) of this section, the reserve sample shall be retained for 1 year after the expiration date of the drug product.                                                                                                                                                                                                                                  |
| 3 month    | (2) For a radioactive drug product, except for nonradioactive reagent kits, the reserve sample shall be retained for:                                                                                                                                                                                                                                                                                                                                  |
|            |                       (i) Three months after the expiration date of the drug product if the expiration dating period of the drug product is 30 days or less; or                                                                                                                                                                                                                                                                                        |
|            |                       (ii) Six months after the expiration date of the drug product if the expiration dating period of the drug product is more than 30 days.                                                                                                                                                                                                                                                                                          |
| 30.0 day   | (2) For a radioactive drug product, except for nonradioactive reagent kits, the reserve sample shall be retained for:                                                                                                                                                                                                                                                                                                                                  |
|            |                       (i) Three months after the expiration date of the drug product if the expiration dating period of the drug product is 30 days or less; or                                                                                                                                                                                                                                                                                        |
|            |                       (ii) Six months after the expiration date of the drug product if the expiration dating period of the drug product is more than 30 days.                                                                                                                                                                                                                                                                                          |
| 6 month    | (2) For a radioactive drug product, except for nonradioactive reagent kits, the reserve sample shall be retained for:                                                                                                                                                                                                                                                                                                                                  |
|            |                       (i) Three months after the expiration date of the drug product if the expiration dating period of the drug product is 30 days or less; or                                                                                                                                                                                                                                                                                        |
|            |                       (ii) Six months after the expiration date of the drug product if the expiration dating period of the drug product is more than 30 days.                                                                                                                                                                                                                                                                                          |
| 30.0 day   | (2) For a radioactive drug product, except for nonradioactive reagent kits, the reserve sample shall be retained for:                                                                                                                                                                                                                                                                                                                                  |
|            |                       (i) Three months after the expiration date of the drug product if the expiration dating period of the drug product is 30 days or less; or                                                                                                                                                                                                                                                                                        |
|            |                       (ii) Six months after the expiration date of the drug product if the expiration dating period of the drug product is more than 30 days.                                                                                                                                                                                                                                                                                          |
| 3.0 year   | (3) For an OTC drug product that is exempt for bearing an expiration date under &#167;&#8201;211.137, the reserve sample must be retained for 3 years after the lot or batch of drug product is distributed.                                                                                                                                                                                                                                           |
| 1.0 year   | (a) Any production, control, or distribution record that is required to be maintained in compliance with this part and is specifically associated with a batch of a drug product shall be retained for at least 1 year after the expiration date of the batch or, in the case of certain OTC drug products lacking expiration dating because they meet the criteria for exemption under &#167;&#8201;211.137, 3 years after distribution of the batch. |
| 3.0 year   | (a) Any production, control, or distribution record that is required to be maintained in compliance with this part and is specifically associated with a batch of a drug product shall be retained for at least 1 year after the expiration date of the batch or, in the case of certain OTC drug products lacking expiration dating because they meet the criteria for exemption under &#167;&#8201;211.137, 3 years after distribution of the batch. |
| 1.0 year   | (b) Records shall be maintained for all components, drug product containers, closures, and labeling for at least 1 year after the expiration date or, in the case of certain OTC drug products lacking expiration dating because they meet the criteria for exemption under &#167;&#8201;211.137, 3 years after distribution of the last lot of drug product incorporating the component or using the container, closure, or labeling.                 |
| 3.0 year   | (b) Records shall be maintained for all components, drug product containers, closures, and labeling for at least 1 year after the expiration date or, in the case of certain OTC drug products lacking expiration dating because they meet the criteria for exemption under &#167;&#8201;211.137, 3 years after distribution of the last lot of drug product incorporating the component or using the container, closure, or labeling.                 |
| 1.0 year   | Written records involving a drug product shall be maintained until at least 1 year after the expiration date of the drug product, or 1 year after the date that the complaint was received, whichever is longer.                                                                                                                                                                                                                                       |
| 1.0 year   | Written records involving a drug product shall be maintained until at least 1 year after the expiration date of the drug product, or 1 year after the date that the complaint was received, whichever is longer.                                                                                                                                                                                                                                       |
| 3.0 year   | In the case of certain OTC drug products lacking expiration dating because they meet the criteria for exemption under &#167;&#8201;211.137, such written records shall be maintained for 3 years after distribution of the drug product.                                                                                                                                                                                                               |


## Condition

| Condition     | Context                                                                                                                                            |
|:--------------|:---------------------------------------------------------------------------------------------------------------------------------------------------|
| unless        | do not supersede the regulations in this part unless  the regulations explicitly provide otherwise.                                                |
| if            | shall not be enforced for OTC drug products if the products and all their ingredients are ordinarily                                               |
| until         | Therefore,  until further notice, regulations under parts 110 and 117                                                                              |
| where         | parts 110 and 117 of this chapter, and where applicable, parts 113 through 129 of this chapter,                                                    |
| if            | to assure that no errors have occurred or, if errors have occurred, that they have been fully                                                      |
| until         | product containers, closures, in-process materials, and drug products until the condition is corrected or determined by competent                  |
| when          | micro-organisms, dust, humidity, and temperature shall be provided when appropriate for the manufacture, processing, packing, or holding           |
| when          | and particulate matter air filters, shall be used when  appropriate on air supplies to production areas.                                           |
| where         | In areas  where air contamination occurs during production, there shall be                                                                         |
| where         | (b) Drains shall be of adequate size and,  where connected directly to a sewer, shall be provided                                                  |
| unless        | Rodenticides, insecticides, and fungicides shall not be used  unless registered and used in accordance with the Federal                            |
| where         | maintaining equipment; (2) Maintenance and cleaning schedules, including, where appropriate, sanitizing schedules; (3) A description in sufficient |
| where         | computer or related system shall be maintained except where certain data, such as calculations performed in connection                             |
| if            | by one person and checking by another person if such equipment is used in conformity with this                                                     |
| when          | Fiber-releasing filters may be used  when it is not possible to manufacture such products                                                          |
| if            | pore size rating of 0.2 micron (0.45 micron if the manufacturing conditions so dictate) shall subsequently be                                      |
| until         | containers, and closures shall be stored under quarantine until they have been tested or examined, whichever is                                    |
| until         | containers, and closures shall be withheld from use until the lot has been sampled, tested, or examined,                                           |
| where         | and the quantity needed for analysis and reserve where  required by &#167;&#8201;211.170.                                                          |
| when          | The containers of components selected shall be cleaned when necessary in a manner to prevent introduction of                                       |
| when          | equipment and aseptic sampling techniques shall be used when  necessary.                                                                           |
| if            | sample subdivisions shall not be composited for testing. if                                                                                        |
| if            | Spec if ic identity tests,                                                                                                                         |
| provided that | be accepted from the supplier of a component, provided that at least one specific identity test is conducted                                       |
| provided that | be accepted from the supplier of a component, provided that at least one specific identity test is conducted                                       |
| provided that | of testing may be accepted from the supplier, provided that at least a visual identification is conducted on                                       |
| provided that | of testing may be accepted from the supplier, provided that at least a visual identification is conducted on                                       |
| when          | (4) When appropriate, components shall be microscopically examined. when                                                                           |
| if            | Deviation from this requirement is permitted  if  such deviation is temporary and appropriate.                                                     |
| where         | product containers and closures shall be clean and, where indicated by the nature of the drug, sterilized                                          |
| where         | (d) Standards or specifications, methods of testing, and,  where indicated, methods of cleaning, sterilizing, and processing to                    |
| when          | containers must be reasonably resistant to fading, durable when exposed to atmospheric conditions, and not readily soluble                         |
| if            | to the batch by one person and ver if ied by a second person or,                                                                                   |
| if            | be performed by one person and independently ver if ied by a second person, or,                                                                    |
| when          | at all times to indicate their contents and, when  necessary, the phase of processing of the batch.                                                |
| where         | In cases  where only one of a particular type of equipment                                                                                         |
| where         | include, but are not limited to, the following, where appropriate: (1) Tablet or capsule weight variation; (2)                                     |
| where         | previous acceptable process average and process variability estimates where possible and determined by the application of suitable                 |
| where         | previous acceptable process average and process variability estimates where possible and determined by the application of suitable                 |
| if            | Deviation from established time limits may be acceptable  if such deviation does not compromise the quality of                                     |
| unless        | contents of the same drug product, is prohibited unless the labeling from gang-printed sheets is adequately differentiated                         |
| if            | of labeling and packaging lines to each d if ferent strength of each d                                                                             |
| when          | product finished and the quantity of labeling issued when such discrepancies are outside narrow preset limits based                                |
| if            | reconciliation is waived for cut or roll labeling if a 100-percent examination for correct labeling is performed                                   |
| if            | an OTC drug product (except a dermatological, dent if rice, insulin, or lozenge product) for retail sale                                           |
| if            | or more indicators or barriers to entry which, if breached or missing, can reasonably be expected to                                               |
| if            | to increase the likelihood that consumers will discover if a product has been tampered with, the package                                           |
| when          | shall be designed to and shall remain intact when handled in a reasonable manner during manufacture, distribution,                                 |
| if            | In order to alert consumers to the spec if ic tamper-evident feature(s) used, each retail package of                                               |
| if            | paragraph (b) of this section uses an ident if ying characteristic, that characteristic is required to be                                          |
| if            | of this chapter and should be clearly ident if ied on the envelope as a &#8220;Request for                                                         |
| subject to    | (e) OTC drug products  subject to  approved new drug applications.                                                                                 |
| if            | for both the reconstituted and unreconstituted drug products. if                                                                                   |
| provided that | are exempt from the requirements of this section, provided that they meet appropriate standards or specifications as demonstrated                  |
| if            | not be enforced for human OTC drug products if their labeling does not bear dosage limitations and                                                 |
| if            | Deviation from this requirement is permitted  if  such deviation is temporary and appropriate.                                                     |
| if            | can be readily determined to facilitate its recall if  necessary.                                                                                  |
| subject to    | component, drug product container, or closure that is subject to  deterioration.                                                                   |
| as soon as    | and/or pyrogen testing, provided such testing is completed as soon as  possible.                                                                   |
| until         | conducted, including drug product testing at appropriate intervals, until the tentative expiration date is verified or the                         |
| if            | of the drug product containing the active ingredient if the expiration dating period of the drug product                                           |
| if            | of the drug product containing the active ingredient if the expiration dating period of the drug product                                           |
| unless        | least once a year for evidence of deterioration unless visual examination would affect the integrity of the                                        |
| if            | after the expiration date of the drug product if the expiration dating period of the drug product                                                  |
| if            | after the expiration date of the drug product if the expiration dating period of the drug product                                                  |
| if            | Such drug product shall not be marketed  if detectable levels are found when tested according to                                                   |
| when          | not be marketed if detectable levels are found when tested according to procedures specified in &#8216;Procedures for                              |
| where         | inspection during the retention period at the establishment where  the activities described in such records occurred.                              |
| subject to    | These records or copies thereof shall be  subject to photocopying or other means of reproduction as part                                           |
| where         | number of batches, whether approved or rejected, and, where  applicable, records associated with the batch.                                        |
| if            | assure that the responsible officials of the firm, if they are not personally involved in or immediately                                           |
| provided that | product, then individual equipment logs are not required, provided that lots or batches of such product follow in                                  |
| where         | In cases  where dedicated equipment is employed, the records of cleaning,                                                                          |
| if            | performing and double-checking the cleaning and maintenance (or, if the cleaning and maintenance is performed using automated                      |
| if            | name of the supplier; the supplier's lot number(s) if  known; the receiving code as spec                                                           |
| if            | The name and location of the prime manufacturer,  if  d                                                                                            |
| if            | The name and location of the prime manufacturer,  if  d                                                                                            |
| if            | dated, and signed; (b) Documentation that each sign if icant step in the manufacture, processing, packing, or                                      |
| where         | with identification of source (that is, location from where sample was obtained), quantity, lot number or other                                    |
| where         | or measure of sample used for each test, where  appropriate.                                                                                       |
| where         | product complaints shall be maintained at the establishment where the drug product involved was manufactured, processed, or                        |
| if            | such file may be maintained at another facility if the written records in such files are readily                                                   |
| until         | records involving a drug product shall be maintained until at least 1 year after the expiration date                                               |
| where         | The written record shall include the following information, where known: the name and strength of the drug                                         |
| where         | include the findings of the investigation and followup. where                                                                                      |
| where         | the investigation shall be maintained at the establishment where  the investigation occurred in accordance with &#167;&#8201;211.180(c).           |
| where         | of the responsible person making such a determination. where                                                                                       |
| if            | or shipped before or during their return, or if the condition of the drug product, its container,                                                  |
| unless        | product, the returned drug product shall be destroyed unless examination, testing, or other investigations prove the drug                          |
| if            | such conditions, salvaging operations may be conducted only if there is (a) evidence from laboratory tests and                                     |
| where         | laboratory tests and assays (including animal feeding studies where applicable) that the drug products meet all applicable                         |
| subject to    | and disposition shall be maintained for drug products subject to  this section.                                                                    |


## Entities

| Entities                   | Context                                                                                                                                  |
|:---------------------------|:-----------------------------------------------------------------------------------------------------------------------------------------|
| Food                       | Food  and Drugs.                                                                                                                         |
| Scope                      | Scope .                                                                                                                                  |
| Personnel                  | Personnel  responsibilities.                                                                                                             |
| Design                     | Design  and construction features.                                                                                                       |
| Ventilation                | Ventilation , air filtration, air heating and cooling.                                                                                   |
| Plumbing                   | Plumbing .                                                                                                                               |
| Potable                    | Potable water shall meet the standards prescribed in the                                                                                 |
| Sewage                     | Sewage  and refuse.                                                                                                                      |
| Sewage                     | Sewage , trash, and other refuse in and from                                                                                             |
| Adequate                   | Adequate washing facilities shall be provided, including hot and                                                                         |
| Sanitation                 | Sanitation .                                                                                                                             |
| Trash                      | Trash and organic waste matter shall be held and                                                                                         |
| Fungicide                  | and used in accordance with the Federal Insecticide, Fungicide , and Rodenticide Act (7 U.S.C. 135).                                     |
| Maintenance                | Maintenance .                                                                                                                            |
| Equipment                  | Equipment  design, size, and location.                                                                                                   |
| Equipment                  | Equipment used in the manufacture, processing, packing, or holding                                                                       |
| Automatic                  | Automatic , mechanical, and electronic equipment.                                                                                        |
| Written                    | Written records of those calibration checks and inspections shall                                                                        |
| Input                      | Input to and output from the computer or related                                                                                         |
| Receipt                    | Receipt and storage of untested components, drug product containers,                                                                     |
| Specific                   | Specific  identity tests, if they exist, shall be used.                                                                                  |
| Drug                       | Drug  product containers and closures.                                                                                                   |
| Such                       | Such  depyrogenation processes shall be validated.                                                                                       |
| Portable                   | Portable cryogenic medical gas containers that are not manufactured                                                                      |
| Written                    | Written  procedures; deviations.                                                                                                         |
| Written                    | Written production and control procedures shall include the following,                                                                   |
| Calculation                | Calculation  of yield.                                                                                                                   |
| Actual                     | Actual yields and percentages of theoretical yield shall be                                                                              |
| Examination                | Examination and testing of samples shall assure that the                                                                                 |
| Such                       | Such  deviation shall be justified and documented.                                                                                       |
| Access                     | Access to the storage area shall be limited to                                                                                           |
| Such                       | Such examination shall be performed by one person and                                                                                    |
| Packaging                  | Packaging  and labeling operations.                                                                                                      |
| Request                    | clearly identified on the envelope as a &#8220; Request for Exemption from the Tamper-Evident Packaging Rule.&#8221; The                 |
| Drug                       | Drug  product inspection.                                                                                                                |
| Expiration                 | Expiration  dating.                                                                                                                      |
| New                        | (g)  New drug products for investigational use are exempt from                                                                           |
| Written                    | Written procedures describing the warehousing of drug products shall                                                                     |
| Distribution               | Distribution  procedures.                                                                                                                |
| Written                    | Written procedures shall be established, and followed, describing the                                                                    |
| Laboratory                 | Laboratory  controls shall include:                                                                                                      |
| Such                       | Such validation and documentation may be accomplished in accordance                                                                      |
| Prior                      | Prior to acceptance and use, reprocessed material must meet                                                                              |
| Accelerated                | Accelerated studies, combined with basic stability information on the                                                                    |
| Reserve                    | Reserve  samples.                                                                                                                        |
| Reserve                    | Reserve samples of compressed medical gases need not be                                                                                  |
| Laboratory                 | Laboratory  animals.                                                                                                                     |
| Penicillin                 | Penicillin  contamination.                                                                                                               |
| Such                       | Such drug product shall not be marketed if detectable                                                                                    |
| Drugs                      | &#8216;Procedures for Detecting and Measuring Penicillin Contamination in Drugs ,&#8217; which is incorporated by reference.             |
| Research and Testing       | Copies are available from the Division of  Research and Testing (HFD-470), Center for Drug Evaluation and Research, Food                 |
| Research                   | Copies are available from the Division of  Research  and Testing (HFD-470), Center for Drug Evaluation and                               |
| Written                    | Written procedures shall be established and followed for such                                                                            |
| Master                     | Master  production and control records.                                                                                                  |
| Batch                      | Batch  production and control records.                                                                                                   |
| Batch                      | Batch production and control records shall be prepared for                                                                               |
| Dates                      | holding of the batch was accomplished, including: (1) Dates ; (2) Identity of individual major equipment and                             |
| Laboratory                 | Laboratory  records.                                                                                                                     |
| United States Pharmacopeia | employed is in the current revision of the United States Pharmacopeia , National Formulary, AOAC INTERNATIONAL, Book of Methods,&#8201;1 |
| Distribution               | Distribution  records.                                                                                                                   |
| Distribution               | Distribution records shall contain the name and strength of                                                                              |
| Written                    | Written records involving a drug product shall be maintained                                                                             |
| Drug                       | Drug  product salvaging.                                                                                                                 |
| Drug                       | Drug products that have been subjected to improper storage                                                                               |
| Organoleptic               | Organoleptic examinations shall be acceptable only as supplemental evidence                                                              |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                     |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1978-09-29 | (c) Pending consideration of a proposed exemption, published in the Federal Register of September 29, 1978, the requirements in this part shall not be enforced for OTC drug products if the products and all their ingredients are ordinarily marketed and consumed as human foods, and which products may also fall within the legal definition of drugs by virtue of their intended use. |
| 1978-09-29 | (h) Pending consideration of a proposed exemption, published in the Federal Register of September 29, 1978, the requirements in this section shall not be enforced for human OTC drug products if their labeling does not bear dosage limitations and they are stable for at least 3 years as supported by appropriate stability data.                                                      |
| 2018-03-01 | (c) For homeopathic drug products, the requirements of this section are as follows:                                                                                                                                                                                                                                                                                                         |
|            |                       (1) There shall be a written assessment of stability based at least on testing or examination of the drug product for compatibility of the ingredients, and based on marketing experience with the drug product to indicate that there is no degradation of the product for the normal or expected period of use.                                                     |


